ReviewClinical pharmacokinetics2020
Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Review in Clinical pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?Diabetic medicine : a journal of the British Diabetic Association · 2026Trial
- Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial.Diabetes, obesity & metabolism · 2026Trial
- Trial
- Fully Closed-Loop Insulin Delivery in Patients Undergoing Pancreatic Surgery.Diabetes technology & therapeutics · 2023Trial
- Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.Diabetes care · 2021Trial
- Glucagon enhances subcutaneous insulin absorption: Pilot experiments in pigs.Current therapeutic research, clinical and experimental · 2026Article
- Article
- Biotechnology Revolution Shaping the Future of Diabetes Management.Biomolecules · 2024Review
- An injectable and biodegradable zwitterionic gel for extending the longevity and performance of insulin infusion catheters.Nature biomedical engineering · 2024Article
- Adjusting Therapy Profiles When Switching to Ultra-Rapid Lispro in an Advanced Hybrid Closed-Loop System: An in Silico Study.Journal of diabetes science and technology · 2024Article
- Diabetes and its Complications: Role of Luteolin, A Wonder Chemical from the Natural Source.Current diabetes reviews · 2024Review
- New therapies towards a better glycemic control in youths with type 1 diabetes.Pharmacological research · 2023Review
- Review
- Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.Diabetes & metabolism journal · 2023Article
- The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes.Nutrients · 2022Article
- Article
- Article
- New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals.The Journal of clinical endocrinology and metabolism · 2022Review
- Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series.Journal of diabetes science and technology · 2021Review
- A Hybrid Automata Approach for Monitoring the Patient in the Loop in Artificial Pancreas Systems.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.